【多发性骨髓瘤的治疗】

Schweizerische medizinische Wochenschrift Pub Date : 2000-11-04

J L Harousseau

{"title":"【多发性骨髓瘤的治疗】","authors":"J L Harousseau","doi":"","DOIUrl":null,"url":null,"abstract":"The chief advances observed over the last 15 years in the treatment of multiple myeloma arise from intensive procedures and in particular autologous bone marrow transplantation. However, even if autologous bone marrow transplantation increases the rate of total remissions, no plateau is yet observable in the survival curve and transplantation is probably not a curative therapy. Hopes for the future seem to rest on intensive chemotherapy combined with innovative therapeutic approaches such as diphosphonates, thalidomide or immunotherapy.","PeriodicalId":21484,"journal":{"name":"Schweizerische medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2000-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Treatment of multiple myeloma].\",\"authors\":\"J L Harousseau\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The chief advances observed over the last 15 years in the treatment of multiple myeloma arise from intensive procedures and in particular autologous bone marrow transplantation. However, even if autologous bone marrow transplantation increases the rate of total remissions, no plateau is yet observable in the survival curve and transplantation is probably not a curative therapy. Hopes for the future seem to rest on intensive chemotherapy combined with innovative therapeutic approaches such as diphosphonates, thalidomide or immunotherapy.\",\"PeriodicalId\":21484,\"journal\":{\"name\":\"Schweizerische medizinische Wochenschrift\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Schweizerische medizinische Wochenschrift\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schweizerische medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在过去15年中，多发性骨髓瘤治疗的主要进展来自于强化手术，特别是自体骨髓移植。然而，即使自体骨髓移植增加了总缓解率，在生存曲线上还没有观察到平台，移植可能不是一种治愈性治疗。对未来的希望似乎取决于强化化疗结合创新的治疗方法，如二磷酸盐，沙利度胺或免疫疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

[Treatment of multiple myeloma].

The chief advances observed over the last 15 years in the treatment of multiple myeloma arise from intensive procedures and in particular autologous bone marrow transplantation. However, even if autologous bone marrow transplantation increases the rate of total remissions, no plateau is yet observable in the survival curve and transplantation is probably not a curative therapy. Hopes for the future seem to rest on intensive chemotherapy combined with innovative therapeutic approaches such as diphosphonates, thalidomide or immunotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Schweizerische medizinische Wochenschrift

自引率

0.00%

发文量